BCR-ABL Transcripts - CML - Chronic Myeloid Leukemia
''Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL1 fusion gene. In over 95% of CML patients, the typical BCR-ABL1 transcript subtypes are e13a2 (b2a2), e14a2 (b3a2) or expression of both simultaneously. Other less frequent transcript subtypes, such as e1a2, e2a2, e6a2, e19a2, e1a3, e13a3 and e14a3, have been sporadically reported.1 Different subtypes of BCR-ABL1 transcripts encode fusion proteins with different sizes that may lead to different disease phenotypes. The e13a2 and e14a2 transcripts encode P210 BCR-ABL1 proteins with slightly different sizes. Patients with the e14a2 transcript have a significantly higher platelet count than those with the e13a2 transcript.2, 3, 4 Patients with the e19a2 transcript, which encodes P230, often present with prominent neutrophilic maturation or thrombocytosis, whereas patients with the e1a2 transcript, which encodes P190, often present with monocytosis, absence of basophilia and a tendency to progress to lymphoid blast phase (BP).5, ""
Extract of Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia, July 14, 2017, Blood Cancer journal
PUBLICATIONS
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
November 2017, Clinical Lymphoma Myeloma & Leukemia
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy ********
2017, Haematologica
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
December 2016, International journal of laboratory hematology
Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR
November 2004, Journal of Molecular Diagnostics
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
November 2017, Clinical Lymphoma Myeloma & Leukemia
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy ********
2017, Haematologica
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
December 2016, International journal of laboratory hematology
Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR
November 2004, Journal of Molecular Diagnostics
ARTICLES
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
September 16, 2020, Oncology Learning Network
FAVORABLE OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CO-EXPRESSING E13A2 AND E14A2 TRANSCRIPT TREATED FRONTLINE WITH NILOTINIB
June 2020, EHA 2020
BCR-ABL1 TRANSCRIPTS E13A2 AND E14A2 IN RELATION TO SURVIVAL AND MOLECULAR RESPONSES IN CML PATIENTS IN BOSNIA
CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START
June 2020, EHA 2020
RARE BCR-ABL TRANSCRIPTS IN CML: E6A2 WITH EXTRAMEDULLARY LESIONS AND UNUSUAL E2A2 WITH PATIAL DELETION AND STIMULTANEOUS INSERTION (CASE REPORTS)
June 2020, EHA 2020
R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients
December 2019, ASH 2019
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
May 2, 2019, BMC Hematology
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor
Health Canada approves two tests for CML patients
November 15, 2018, MDedge
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors ********
December 2017, ASH 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
July 14, 2017, Blood Cancer journal
BCR-ABL Transcript Type Predicts Response and Survival Among Patients with CML
February 1, 2016, ASH Clinical News
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
May 6, 2014, Leukemia
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
July 2, 2012, Hindawi
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
November 19, 2010, BMC Hematology
Dual transcription of b2a2 and b3a2 BCR–ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene
June 10, 2002, British Journal of Haematology
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
September 16, 2020, Oncology Learning Network
FAVORABLE OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CO-EXPRESSING E13A2 AND E14A2 TRANSCRIPT TREATED FRONTLINE WITH NILOTINIB
June 2020, EHA 2020
BCR-ABL1 TRANSCRIPTS E13A2 AND E14A2 IN RELATION TO SURVIVAL AND MOLECULAR RESPONSES IN CML PATIENTS IN BOSNIA
CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START
June 2020, EHA 2020
RARE BCR-ABL TRANSCRIPTS IN CML: E6A2 WITH EXTRAMEDULLARY LESIONS AND UNUSUAL E2A2 WITH PATIAL DELETION AND STIMULTANEOUS INSERTION (CASE REPORTS)
June 2020, EHA 2020
R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients
December 2019, ASH 2019
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
May 2, 2019, BMC Hematology
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor
Health Canada approves two tests for CML patients
November 15, 2018, MDedge
An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors ********
December 2017, ASH 2017
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
July 14, 2017, Blood Cancer journal
BCR-ABL Transcript Type Predicts Response and Survival Among Patients with CML
February 1, 2016, ASH Clinical News
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
May 6, 2014, Leukemia
Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
July 2, 2012, Hindawi
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
November 19, 2010, BMC Hematology
Dual transcription of b2a2 and b3a2 BCR–ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene
June 10, 2002, British Journal of Haematology
